CN116270682A - Ginsenoside Rg 1 Application of medicine in preparation of medicine for treating alcoholic liver injury - Google Patents
Ginsenoside Rg 1 Application of medicine in preparation of medicine for treating alcoholic liver injury Download PDFInfo
- Publication number
- CN116270682A CN116270682A CN202310299683.4A CN202310299683A CN116270682A CN 116270682 A CN116270682 A CN 116270682A CN 202310299683 A CN202310299683 A CN 202310299683A CN 116270682 A CN116270682 A CN 116270682A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- liver injury
- alcoholic liver
- treating alcoholic
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 49
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 45
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 41
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 3
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 title abstract description 16
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 title abstract description 16
- 102100035904 Caspase-1 Human genes 0.000 claims abstract description 10
- 108090000426 Caspase-1 Proteins 0.000 claims abstract description 10
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract description 10
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims abstract description 10
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 8
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 8
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 210000004185 liver Anatomy 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000001154 acute effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 231100000439 acute liver injury Toxicity 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 231100000012 chronic liver injury Toxicity 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 7
- 230000007850 degeneration Effects 0.000 abstract description 4
- 102000003929 Transaminases Human genes 0.000 abstract description 3
- 108090000340 Transaminases Proteins 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 15
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 12
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a ginsenoside Rg 1 An application in preparing a medicament for treating alcoholic liver injury belongs to the field of medicaments. The invention uses ginsenoside Rg 1 For treating alcoholic liver injury, specifically ginsenoside Rg 1 Use of ginsenoside Rg for improving alcoholic liver injury by inhibiting NLRP3 inflammatory body/caspase-1 signaling pathway 1 After administration, the fatty degeneration of the liver of the organism is reduced, and the contents of transaminase indexes AST, ALT and TG in serum are obviously reduced, which indicates that ginsenoside Rg1 can improve alcoholic liver injury.
Description
Technical Field
The invention relates to a ginsenoside Rg 1 An application in preparing a medicament for treating alcoholic liver injury belongs to the field of medicaments.
Background
Alcoholic liver injury is a common liver disease, a complex pro-inflammatory process that can lead to steatosis, alcoholic hepatitis, fibrosis, and ultimately cirrhosis. About up to 90% of severe drinkers (ethanol consumption >60 g/day) experience steatosis, with about 35% experiencing more severe alcoholic liver disease. Alcoholic fatty liver is generally asymptomatic and has long been considered benign because it may reverse completely after about 4-6 weeks. However, some studies indicate that 5-15% of alcoholic fatty liver patients will continue to progress from steatosis to fibrosis and cirrhosis. Alcoholic hepatitis is characterized by inflammatory cell infiltration into the liver and hepatic cell injury, which occurs in patients with fatty liver degeneration, often associated with progressive fibrosis. Alcoholic cirrhosis is the end stage of alcoholic liver injury, endangering the life safety of the patient. The deleterious effects of ethanol on the liver have been studied for about 60 years and alcoholic liver injury is now widely recognized as a multifactorial disease, with parenchymal and non-parenchymal cells in the liver and other types of liver cells involved in the pathogenesis of alcoholic liver injury. Although treatments for alcoholic liver injury are under development, their efficacy and safety issues are limited. Therefore, the development of safe and effective drugs and foods for resisting alcoholic liver injury has important significance.
Ginseng (Panax ginseng c.a. mey.) is a dried root and rhizome of ginseng, a perennial herb of the araliaceae family, and is a valuable edible and medicinal plant. Ginsenoside is one of the main pharmacological active ingredients of Ginseng radix, wherein ginsenoside Rg 1 (Ginsenoside Rg 1 ) Is a key bioactive component. Ginsenoside Rg 1 Has various biological activities such as anti-inflammatory, antioxidant, antihypoxic, antiaging, immunity enhancing, and memory improving effects. There is also an increasing number of studies demonstrating its effective role in a variety of liver diseases.
Disclosure of Invention
One of the purposes of the present invention is to provide ginsenoside Rg 1 Application in preparing medicine for treating alcoholic liver injury is provided.
Another object of the present invention is ginsenoside Rg 1 Application in preparing medicine for treating alcoholic fatty liver.
The technical scheme of the invention is as follows:
ginsenoside Rg 1 Application in preparing medicine for treating alcoholic liver injury is provided.
Further defined, alcoholic liver injury includes acute or chronic liver injury caused by alcohol.
Further defined, the agent for treating alcoholic liver injury refers to inhibiting NLRP3 inflammatory corpuscle or caspase-1 signaling pathway.
The invention also provides a pharmaceutical composition for treating alcoholic liver injury, and the pharmaceutical composition specifically comprises ginsenoside Rg1 as an active ingredient and a pharmaceutically acceptable carrier.
Further defined, the molecular structure of ginsenoside Rg1 is as follows:
further defined, the pharmaceutical composition is in the form of a tablet capsule, pill, granule, powder, paste, mixture, suspension or liquid formulation.
The invention also provides a food for relieving liver injury caused by alcohol, and the food specifically contains ginsenoside Rg1.
The invention also provides a pharmaceutical compound for treating alcoholic liver injury.
The invention also provides a health care product for assisting in relieving liver injury caused by alcohol, and the health care product specifically contains ginsenoside Rg 1 。
The invention has the following beneficial effects: the invention uses ginsenoside Rg 1 For treating alcoholic liver injury, specifically ginsenoside Rg 1 Use of ginsenoside Rg for improving alcoholic liver injury by inhibiting NLRP3 inflammatory body/caspase-1 signaling pathway 1 After administration, the fatty degeneration of the organism liver is reduced, and the contents of transaminase indexes AST, ALT and TG in serum are obviously reduced, which indicates that ginsenoside Rg 1 Can be used for improving alcoholic liver injury.
Drawings
FIG. 1 shows the ginsenoside Rg at different doses 1 Influence on pathological changes of liver tissues of mice with acute alcoholic liver injury;
FIG. 2 shows the ginsenoside Rg at different doses 1 Effect on acute alcoholic liver injury mice NLRP3 inflammatory body/caspase-1 protein.
Detailed Description
The present invention will be described in further detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, methods and apparatus used, without any particular description, are those conventional in the art and are commercially available to those skilled in the art.
Example 1: the invention will be further described with reference to the accompanying drawings and specific experiments.
1. Experimental materials
1.1 laboratory animals
ICR mice were purchased from the company, inc. SCXK (Liao) 2020-0001.
1.2 drugs and Agents
Alanine aminotransferase (alanine aminotransferase, ALT), aspartate Aminotransferase (AST) and Triglyceride (TG) kits were purchased from the institute of bioengineering, build-up bioengineering, south kyo; the BCA method total protein quantitative assay kit was purchased from the bio-tech company of bi yun.
2. Experimental method
2.1 establishment of acute alcohol model
ICR mice were randomized to normal groups, alcohol group (i.e., model group), low dose group (5 mg/kg), medium dose group (10 mg/kg), high dose group (20 mg/kg) of ginsenoside Rg1, 8 per group after one week adaptation. Each treatment group was given a corresponding therapeutic drug for 7 consecutive days, 1 time per day, and normal and model groups were perfused with an equal volume of physiological saline. After 7 days, except for the normal group, the stomach is irrigated with 50% ethanol (6 g/kg) by volume fraction, and a model of acute alcoholic liver injury of the once-through fulminant mice is established. The last 1 day of administration was fasted for 12h, after 12h, the eyeballs were taken for blood collection after anesthesia with diethyl ether, and the livers were isolated and stored in a refrigerator at-80 ℃.
2.2 detection of Biochemical indicators
The serum of the mice was tested for glutamic-oxaloacetic transaminase (aspartate aminotransferase, AST), glutamic-pyruvic transaminase (alanine aminotransferase, ALT), triglyceride (TG) content.
2.3 protein imprinting method to detect the expression of proteins in liver tissue
The protein concentration of cells is measured by BCA method, SDS-PAGE (10% -12%) separation gel is used for separating the same amount of protein samples, the protein samples are transferred to PVDF membrane, the protein samples are blocked for 1h, incubated by primary antibody, and then placed overnight at 4 ℃ and incubated for 1h at room temperature by using enzyme-labeled secondary antibody. And (3) mixing the reagent A and the reagent B in equal volumes, fully contacting the PVDF film with the mixed solution, and exposing in a full-function imaging system.
2.4 statistical analysis
Data were processed using statistical analysis, experimental results
Data analysis was performed using Graphpad Prism5 (Graphpad software, inc, san Diego, USA) software, and data were compared using One-way anova (One-way anova) and Turkey's multifactor t-test.
3. Experimental results
3.1 Effect of ginsenoside Rg1 on alcoholic liver injury mice AST, ALT and TG
ALT and AST are main functional enzymes in liver cells, are signals of liver cell injury, and another concurrent symptom possibly caused by alcohol entering the body is lipid metabolism abnormality, so that the detection of the activity of ALT and AST and the TG content in serum can accurately reflect the degree of early alcoholic liver injury.
The results are shown in table 1 below, and the activity of ALT, AST and TG in the serum of mice in the model group were significantly increased (P <0.01, P < 0.001) compared to the normal group, indicating primarily that acute alcohol was able to induce liver injury. The ginsenoside Rg1 can obviously reduce the contents of ALT, AST and TG in serum of mice (P is less than 0.01, P is less than 0.05), which indicates that the ginsenoside Rg1 can inhibit alcoholic liver injury and reduce TG accumulation in liver.
TABLE 1 Effect of ginsenoside Rg1 on mice with acute alcoholic liver injury
Note that: in comparison with the normal group, ## P<0.001, compared to the model set, ** P<0.01， * P<0.05
3.2 Effect of ginsenoside Rg1 on pathological changes of liver tissue of mice with acute alcoholic liver injury
The results are shown in FIG. 1, and H & E staining results show that the normal group mice have regular arrangement of hepatic cell lines and normal morphology (normal group in FIG. 1); the presence of large numbers of white lipid droplets, fatty vacuolation, and inflammatory cell infiltration in cells in liver tissue of the ETOH group mice; the mouse liver cell lipid drop number in Rg1 group gradually decreased, and the inflammatory infiltration degree was reduced.
3.3 Effect of ginsenoside Rg1 on acute alcoholic liver injury mice NLRP3 inflammatory body/caspase-1 protein
The expression levels of NLRP3 and caspase-1 proteins are detected by adopting Westernblot, as shown in figure 1, compared with a normal group, the expression levels of NLRP3 and caspase-1 in the ETOH group are obviously increased; compared with the ETOH group, the expression level of NLRP3 and caspase-1 in liver tissues of mice in low, medium and high administration groups of Rg1 is obviously reduced, and the dosage dependency is certain.
In conclusion, ginsenoside Rg1 improves alcoholic liver injury by inhibiting NLRP3 inflammatory corpuscle/caspase-1 signal path, fatty degeneration of organism liver is reduced after ginsenoside Rg1 is dosed, and transaminase indexes AST, ALT and TG content in serum are obviously reduced, which indicates that ginsenoside Rg1 can improve alcoholic liver injury.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (9)
1. Ginsenoside Rg 1 Application in preparing medicine for treating alcoholic liver injury is provided.
2. Ginsenoside Rg of claim 1 1 The application of the medicine for treating alcoholic liver injury is characterized in that the alcoholic liver injury comprises acute or chronic liver injury caused by alcohol.
3. Ginsenoside Rg of claim 1 1 The application of the drug for treating alcoholic liver injury in preparation of the drug for treating alcoholic liver injury is characterized in that the drug for treating alcoholic liver injury is used for inhibiting NLRP3 inflammatory corpuscle or caspase-1 signal path.
4. A pharmaceutical composition for treating alcoholic liver injury, characterized in that the pharmaceutical composition comprises ginsenoside Rg as an active ingredient 1 And a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4, wherein ginsenoside Rg 1 The molecular structure of (2) is as follows:
6. the pharmaceutical composition of claim 4, wherein the pharmaceutical composition is in the form of a tablet capsule, pill, granule, powder, paste, mixture, suspension, or liquid formulation.
7. A food for alleviating liver injury caused by alcohol is characterized by comprising ginsenoside Rg 1 。
8. Pharmaceutical compound for treating alcoholic liver injuryCharacterized in that the active ingredient of the compound has ginsenoside Rg 1 The molecular structure includes, but is not limited to, a pharmaceutically acceptable salt, ester, prodrug, solvate, polymorph, hydrate or derivative.
9. A health product for assisting in relieving liver injury caused by alcohol is characterized by comprising ginsenoside Rg 1 。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310299683.4A CN116270682A (en) | 2023-03-25 | 2023-03-25 | Ginsenoside Rg 1 Application of medicine in preparation of medicine for treating alcoholic liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310299683.4A CN116270682A (en) | 2023-03-25 | 2023-03-25 | Ginsenoside Rg 1 Application of medicine in preparation of medicine for treating alcoholic liver injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116270682A true CN116270682A (en) | 2023-06-23 |
Family
ID=86797601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310299683.4A Pending CN116270682A (en) | 2023-03-25 | 2023-03-25 | Ginsenoside Rg 1 Application of medicine in preparation of medicine for treating alcoholic liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116270682A (en) |
-
2023
- 2023-03-25 CN CN202310299683.4A patent/CN116270682A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Levy et al. | Use of herbal supplements for chronic liver disease | |
| CN111110824B (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| CN105535048A (en) | Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout | |
| AU2019100729A4 (en) | Compound Composition of Sunflower Head and Coix Seed and Use Thereof in Treatment of Liver Injury | |
| Liang et al. | Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic | |
| Chiang et al. | Adlay seed (Coix lacryma-jobi L.) extracts exhibit a prophylactic effect on diet-induced metabolic dysfunction and nonalcoholic fatty liver disease in mice | |
| WO2022062715A1 (en) | Composition with effect of lowering blood lipids and preparation method therefor and use thereof | |
| EP3833370A1 (en) | Compositions for use in the treatment of obesity | |
| Shi et al. | Saponin extract from Achyranthes bidentata Blume alleviates disuse-induced muscle atrophy through PI3K/Akt signaling pathway | |
| CN109939153A (en) | A kind of anaesthetic for treating enteritis and preparation method thereof and preparation and preparation method | |
| Jiang et al. | Preventive mechanisms of Chinese Tibetan medicine Triphala against nonalcoholic fatty liver disease | |
| WO2016169490A1 (en) | Application of forsythin, forsythin derivative, and composition forsythin and forsythin lignans of in preparing medicine for preventing or/and treating hyperlipidemia | |
| CN117503782A (en) | Application of ginsenoside CK in preparing medicine for preventing and treating immune hepatitis | |
| CN116270682A (en) | Ginsenoside Rg 1 Application of medicine in preparation of medicine for treating alcoholic liver injury | |
| CN108904484A (en) | A kind of purposes of progallin A | |
| CN104856986A (en) | New application of 5-hydroxymethyl-2-furaldehyde (5-HMF) in preparation of anti-liver fibrosis medicine | |
| WO2017121333A1 (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| CN103751174B (en) | Fructus Schisandrae Chinensis monomeric compound is preparing the application in hepatotoxic medication caused by prevention and therapy acetaminophen | |
| CN112457423A (en) | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof | |
| CN106955331B (en) | A kind of pharmaceutical composition for treating chronic renal failure | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN113559189A (en) | Traditional Chinese medicine composition for treating dermatitis or eczema | |
| WO2005072757A1 (en) | Imperatae rhizoma extract for treatment and prevention of obesity | |
| JP2022511544A (en) | Chinese herbal medicine composition for bowel movement, its preparation method and its use | |
| CN114129572B (en) | Pharmaceutical composition for synergistically inhibiting tetrandrine-induced drug-induced liver injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |